Lefluonia (Leflunomide)

Leflunomide blocks the enzyme dihydroorotate dehydrogenase, which is essential for making pyrimidine nucleotides. By limiting pyrimidine synthesis, the drug suppresses the proliferation of activated lymphocytes, thereby dampening the immune response that drives inflammatory arthritis.

The specific dose of Lefluonia is determined by the prescribing physician based on the individual’s clinical condition, laboratory values, and response to therapy. Dosage adjustments may be made after initial assessment and periodic monitoring.

Lefluonia is classified as pregnancy category X, meaning it is contraindicated in pregnancy because it can cause fetal harm. It is also not recommended while breastfeeding, as leflunomide can be excreted in breast milk and may affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Leflunomide is an oral synthetic DMARD that differs from biologic agents such as TNF‑α inhibitors. It offers the convenience of once‑daily oral dosing and does not require injection, but it carries a distinct safety profile, including potential liver toxicity and teratogenicity, which must be weighed against efficacy.

Lefluonia tablets should be stored below 25 °C in their original container, protected from moisture and direct sunlight. Keeping the product in a dry, temperature‑controlled environment helps maintain its stability and potency throughout its shelf life.

Lefluonia is taken orally, usually as a whole tablet with water. It is generally recommended to swallow the tablet whole and not to crush or split it unless specifically instructed by a healthcare professional.

The most serious risks include severe liver injury, bone‑marrow suppression leading to anemia or low white‑blood‑cell counts, pulmonary toxicity such as interstitial lung disease, and rare but life‑threatening skin reactions like Stevens‑Johnson syndrome. Regular monitoring helps detect these complications early.

Lefluonia should not be used by pregnant women, individuals with severe liver disease, uncontrolled hypertension, or known hypersensitivity to leflunomide. It is also contraindicated in patients receiving certain live vaccines or those with severe renal impairment without appropriate dose adjustment.